Serious lung disease is appearing faster than anyone expected
In A Coruña this week, a leading Spanish pulmonologist placed before his colleagues a warning that reframes a widely held assumption: that vaping is a safer passage away from cigarettes. The lung damage now appearing in Spanish clinics — in people who have vaped for only a short time — echoes the pneumonia patterns of early COVID-19, arriving faster than medicine or policy anticipated. It is a reminder that the distance between perceived safety and actual harm is often measured not in years, but in the quiet accumulation of damage no one thought to look for yet.
- Doctors in Spain are documenting severe pulmonary injury in e-cigarette users with relatively brief vaping histories, shattering assumptions about a safe threshold of use.
- The lung damage mirrors the aggressive pneumonia patterns seen in early COVID-19 patients — a comparison that has sharpened alarm within the respiratory medicine community.
- Spain has no national strategy for managing respiratory disease, leaving an accelerating clinical crisis to be absorbed unevenly across regional systems and individual hospitals.
- Regulation across Europe has focused on marketing and youth access, while medical evidence of serious pulmonary harm has outpaced any coordinated policy response.
- Pulmonologist David de la Rosa is pressing the case publicly — but without the backing of national public health infrastructure, the warning risks echoing in a policy vacuum.
David de la Rosa, president of Spain's pulmonologists' association, delivered a striking warning this week at a respiratory disease forum in Galicia: serious lung disease is now appearing in people who have been vaping for only a relatively short time. The cases, he explained, are not theoretical. They are patients in hospitals now, struggling to breathe, their lung tissue scarred by something they believed was a safer alternative to cigarettes.
What has alarmed clinicians is not just the severity of the damage, but its resemblance to the pneumonia patterns documented during the first wave of COVID-19 — aggressive, distinctive, and requiring significant medical intervention. The patients presenting with these injuries have never had COVID. The culprit is a device marketed as a modern convenience.
The timeline is what makes de la Rosa's warning particularly urgent. These are not long-term users. The disease is emerging in people with relatively recent vaping histories, suggesting the threshold for serious harm may be far lower than previously assumed. Someone might choose an e-cigarette believing they are making a responsible decision, only to find themselves months later with compromised lung function.
The clinical picture is compounded by a policy gap. Spain lacks a national strategy for respiratory disease management, meaning the infrastructure to respond to accumulating cases remains fragmented across regions. Across Europe more broadly, regulation has concentrated on marketing restrictions and youth access, while the medical evidence of pulmonary injury has moved faster than legislative response.
De la Rosa's message is unambiguous: the evidence is no longer preliminary, and the medical community is documenting what policymakers have yet to fully reckon with. Whether that reckoning arrives with the urgency the evidence demands remains an open question.
David de la Rosa, president of Spain's pulmonologists' association, stood before an audience in A Coruña this week with a warning that cuts against the common perception of vaping as a safer alternative to cigarettes. Doctors are now seeing serious lung disease in people who have been using e-cigarettes for only a relatively short time—a pattern that has begun to alarm the medical community.
The cases emerging in Spanish clinics bear a striking resemblance to the pneumonia patterns that devastated patients during the first wave of COVID-19. The lung damage induced by e-cigarettes, de la Rosa explained, is appearing with a speed and severity that suggests vaping carries risks far greater than many users understand. These are not theoretical concerns or distant possibilities. They are patients in hospitals now, struggling to breathe, their lungs scarred by something they believed was harmless.
The ninth Forum on Patients with Respiratory Diseases, held in Galicia, provided the platform for this conversation—one that extends beyond the clinical realm into questions of public health policy. Spain, despite the mounting evidence of respiratory illness, lacks coherent national strategies for managing lung disease. While other conditions have drawn coordinated national responses, respiratory diseases have been left to fragment across regional systems and individual hospitals. This gap in planning means that as cases accumulate, the infrastructure to respond remains incomplete.
The comparison to COVID-19 is not casual. During the pandemic's early months, doctors watched as the virus attacked the lungs in ways that seemed to defy conventional understanding. The pneumonia it caused was distinctive, aggressive, and often required intensive intervention. Now, in patients who have never had COVID, doctors are documenting similar patterns of pulmonary injury—but the culprit is not a virus. It is a device marketed as a modern convenience, a way to satisfy nicotine dependence without the tar and smoke of traditional cigarettes.
What makes de la Rosa's warning particularly significant is the timeline. These are not people who have been vaping for decades. The disease is appearing in relatively recent users, which suggests that the threshold for serious harm may be lower than previously assumed. A person might pick up an e-cigarette thinking they are making a safer choice, only to find themselves months later in a pulmonologist's office with scarred lung tissue and compromised breathing capacity.
The broader context is one of policy lag. Public health systems across Europe have been slow to grapple with the long-term consequences of vaping. Regulation has focused primarily on marketing and sales to minors, but the medical evidence of pulmonary injury has accumulated faster than policy responses. Spain's lack of a national respiratory disease strategy means that individual doctors like de la Rosa must sound the alarm without the backing of coordinated public health infrastructure.
For patients already dealing with respiratory illness, the situation is compounded by cost. Breathing difficulties are not merely medical problems—they are economic ones. Treatment, monitoring, and management of lung disease place financial burdens on individuals and families. The absence of national strategies means these costs are borne unevenly, with some regions better equipped than others to support those whose lungs have been damaged.
De la Rosa's message, delivered in A Coruña, is clear: the evidence is no longer preliminary. Serious lung disease from vaping is not a future risk. It is happening now, in people who thought they were making a reasonable choice. The medical community is watching, documenting, and warning. What remains to be seen is whether policymakers will respond with the urgency the evidence demands.
Notable Quotes
Serious lung disease is already being documented in people who have been vaping for a relatively short time— David de la Rosa, president of Spain's pulmonologists' association
The lung damage induced by e-cigarettes resembles the pneumonia patterns seen in early COVID-19 cases— David de la Rosa
The Hearth Conversation Another angle on the story
When you say the damage looks like COVID pneumonia, what exactly do you mean? Are the lungs scarred in the same way?
The pattern of injury is similar—inflammation, fluid accumulation, areas of the lung that stop functioning properly. But with vaping, there's no virus. It's the chemicals in the vapor itself causing the damage directly to lung tissue.
How quickly does this happen? Are we talking months or years?
That's what's alarming doctors. Some of these patients have only been vaping for a relatively short time. It's not a slow, gradual decline. Serious disease is appearing faster than anyone expected.
Why hasn't Spain developed a national strategy for respiratory disease if this is becoming more common?
That's the frustrating part. There are national strategies for cancer, heart disease, diabetes. But respiratory illness has been fragmented—handled regionally, case by case. Now that vaping-related lung damage is emerging, there's no coordinated system ready to respond.
What happens to a patient once they're diagnosed with vaping-induced lung damage?
They need ongoing monitoring, sometimes medication, sometimes oxygen support. But the real problem is that treatment is expensive and access varies depending on where you live. Some regions have better resources than others.
Do these patients recover?
That's still unclear. Some damage may be permanent. We're still learning the long-term trajectory. That's why early warning matters—to prevent more people from getting to that point.
What would de la Rosa want policymakers to hear from his warning?
That this isn't theoretical anymore. It's real patients in real hospitals. And without a coordinated national response, we're going to see more cases, more suffering, and more fragmented care.